MarketInOut Stock Screener Log In | Sign Up

Akari Therapeutics Plc ADR

NASDAQ • Healthcare • Biotechnology • Quote as of 11/13/2026 09:31
Akari Therapeutics Plc ADR stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization17.02 mln
Float1.74 mln
Earnings Date11/13/2026

Piotroski F-Score

4 / 9
Borderline

Relative Strength

9 / 100
Severely lagging

Debt / Equity

0.04
Debt-free

ROE

-141
Deeply negative

ROA

-71.26
Deeply negative

Business Description

Akari Therapeutics Plc is a Boston-based cancer research company focused on creating a new class of precision medicines designed to destroy tumor cells while activating the body's own immune system. Its most advanced program, AKTX-101, targets a protein commonly found on solid tumors ? including those of the lung, breast, colon, and prostate ? by delivering specialized cell-killing agents directly to cancer tissue. The company is also advancing AKTX-102, a dual-targeting treatment, alongside additional compounds engineered to interfere with how cancer cells copy and repair their DNA. Together, these programs reflect Akari's broader strategy of building a pipeline of highly targeted therapies that attack cancer through multiple biological pathways.

Key Fundamentals

EPS-19.78
ROE-141
ROIC-25.19
ROA-71.26
Interest Cover-31.49
EBITDA, mln-31.77
EV / EBITDA-0.26
EV / EBIT-0.26

Quote Details

Last 6.52
Change 0.01 (0.15%)
Open 6.52
Volume 787
Turnover 5,131.24
Average Volume 40,265

Financial Ratios

Leverage Ratio2.08
Current Ratio0.60
Price / Book0.81
Debt / Equity0.04

Financial Strength

Piotroski F-Score 4 / 9
Short Ratio0.41
Short % of Float1.41

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week -11.53% 9 / 100   
1 Month -26.24% 14 / 100   
2 Months -13.41% 38 / 100   
6 Months 86.82% 98 / 100   
1 Year -69.98% 11 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog